&nbsp;

PanCanadianReviewProcess-FR.png

Nov 2022

Statistical Reports

Prevention System Quality Index: Special Report on Cancer Prevention for People Living with Serious Mental Illness

Document

SelectedCancerRiskAmongFirefighters.png

Nov 2022

Document

SelectedCancerRiskAmongFirefighters-FR.png

Nov 2022

Document

Statistiques-sur-le-cancer-en-Ontario-2022.pdf

Nov 2022

Document

SpecialReportCancerPreventionPeopleLivingSeriousMentalIllness.pdf

Dec 2022

Document

SpecialReportCancerPreventionPeopleLivingSeriousMentalIllness-FR.pdf

Dec 2022

Document

SleepWebinarQA.pdf

Dec 2022

Regimen

PC

Cancer Type:

Central Nervous System

Intent: Adjuvant, Curative, Palliative

Funding:

ODB - General Benefit

procarbazine

ODB - General Benefit

lomustine

Drugs Used:

lomustine,

procarbazine

Quick Link(s):

Regimen Monograph

Jan 2023

Regimen

PACL+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

PACL(W)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

PACL(DD)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel